A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414 · Not yet recruiting

Last updated 2026-05-28

This study is testing two different doses of the medication CagriSema and one dose of Semaglutide to see how well they help people with obesity, with or without type 2 diabetes, lose weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 2,500 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-05 · est. completion 2028-04

Where 302 sites · Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, Spain, United States

What this study is testing ClinicalTrials.gov NCT07564414 ↗

Description as written by the study sponsor.

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Treatments tested

Cagrisema Drug

Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07564414 ↗